Property and equipment consisted of the following at December 31:
Range of
useful lives
20252024
Computer equipment
3 – 5 years
$577,715 $514,174 
Office equipment
3 – 15 years 
804,608 792,903 
Furniture and fixtures
5 – 15 years
543,125 537,057 
Leasehold improvements
3 – 15 years, or remaining lease term
841,663 825,074 
Total property and
equipment, gross
2,767,111 2,669,208 
Less: accumulated depreciation
and amortization
(2,502,387)(2,391,843)
Total property and
equipment, net
$264,724 $277,365 
Free Sentinel

Want the next CUMBERLAND PHARMACEUTICALS INC pp&e disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment CUMBERLAND PHARMACEUTICALS INC's next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 9, 2026Showing above
2024Mar 7, 2025
2023Mar 13, 2024
2022Mar 13, 2023
2021Mar 11, 2022
2020Mar 12, 2021
2019Mar 20, 2020
2018Mar 12, 2019
2017Mar 9, 2018
2016Mar 13, 2017
2015Mar 14, 2016

About PP&E Disclosures

The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.

Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.